Johnson & Johnson vs Penumbra, Inc.
JNJ vs PEN — side-by-side comparison from reported financials. JNJ leads 7, PEN leads 2 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Penumbra, Inc.
PEN · Healthcare
$319.40+0.59%Strong
| Metric | JNJ | PEN |
|---|---|---|
| Price | $261.79 | $319.40 |
| Market cap | $631B | $12.6B |
| Revenue (TTM) | $97.9B | $1.50B |
| Revenue growth | +5.6% | +18.3% |
| Net margin | 21.5% | 10.7% |
| Free cash flow | $22.2B | $216M |
| Net cash (debt) | ($27.8B) | — |
| 1-year price return | +37.0% | +22.2% |
| P/E | 29.9 | 78.3 |
| P/E vs own history (cheap-side %) | 16% | 76% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 11% |
| Altman Z-score | — | 18.49 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 140,800 | 4,700 |
Full résumé-style profiles: JNJ CV · PEN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.